STOCK TITAN

Optimi Health - OPTHF STOCK NEWS

Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.

Optimi Health Corp. (OPTHF) is a leading Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA. The company recently obtained a Drug Establishment Licence (DEL) from Health Canada, confirming compliance with Good Manufacturing Practices (GMP). This allows Optimi to supply MDMA and psilocybin capsules to patients with PTSD and Treatment-Resistant Depression under Australia's Authorized Prescriber Scheme and export to regulated jurisdictions globally. Optimi aims to be the trusted global supplier of safe drug candidates by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Rhea-AI Summary

Optimi Health Corp. has announced the successful production of its proprietary MDMA drug candidate, OPTI-MHCL, under Good Manufacturing Practices (GMP) at its facility in Princeton, British Columbia. The drug, which demonstrates a purity of over 99%, is intended for clinical trials and patient access through Health Canada’s Special Access Program and Australia’s Authorized Prescriber Scheme.

Optimi aims to meet the growing global demand for MDMA, particularly with advancements towards FDA approval for MDMA-assisted therapy for PTSD. This end-to-end manufacturing process positions Optimi as a significant supplier in the psychedelics market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.1%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp (OTCQX: OPTHF) announced a significant expansion of its sales network in Canada on January 17, 2023. The company, licensed by Health Canada, produces natural psilocybin and functional mushrooms. Key partnerships have been formed with Purity Life Health Products for distribution and M2 Brand Management as the exclusive retail broker to increase brand presence. Products will be sold online via Amazon.ca and at six Holt Renfrew locations by February 2023. The CEO has emphasized that this expansion is a critical part of their revenue strategy moving forward.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. announces the re-election of five board members following its Annual General Meeting on January 9, 2023. The directors re-elected include Bryan Safarik, Jacob Safarik, Jon Schintler, Dane Stevens, and JJ Wilson. The company also expressed gratitude to outgoing director Michael Stier. Additionally, Smythe LLP was re-appointed as the auditor, and the Company’s Equity Incentive Plan was re-approved. Optimi operates under Health Canada regulations, focusing on natural and synthetic psychedelic substances and functional mushrooms for the wellness market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
management
Rhea-AI Summary

Optimi Health applauds Alberta's decision to regulate psychedelics for therapeutic use, highlighting the importance of a safe supply of psilocybin and MDMA for mental health treatment. Effective January 16, 2023, physicians will be able to prescribe these substances for treatment-resistant conditions. As the largest cultivator of EU-GMP psilocybin and MDMA in North America, Optimi is strategically positioned to support the province's new framework. The company's CEO describes this regulatory move as politically courageous, reaffirming the clinical benefits of psychedelics in addressing mental health challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.1%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp (OTCQX: OPTHF) announced plans to initiate a Phase I clinical trial in collaboration with ATMA Journey Centers to assess the safety of its natural psilocybin and MDMA formulations in healthy subjects. This trial, pending Health Canada's approval, aims to gather critical health data including blood pressure and heart rate, marking a significant milestone towards commercialization. Following ATMA's previous trial success, Optimi's CEO expressed confidence in the demand for these therapies among healthcare professionals, who are awaiting effective psychedelic solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
-
Rhea-AI Summary

Optimi Health Corp. has announced the completion of what it believes to be Canada's largest legal natural psilocybin harvest. Achieving over 150 kg of Panaeolus cyanescens and Psilocybe cubensis, the harvest will undergo rigorous analytical testing before global distribution. The company is licensed by Health Canada and focuses on producing EU-GMP grade psilocybin, MDMA, and functional mushrooms, emphasizing quality and potency. This development supports planned clinical trials aimed at addressing mental health issues such as depression and PTSD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
Rhea-AI Summary

Optimi Health Corp. (OTCQX: OPTHF) has entered a large-scale international distribution agreement with Avida Global, a UK-based wellness products producer. Optimi will supply Avida with its functional mushroom supplement formulations, making Avida the exclusive distributor in several countries including the UK, EU, and Japan. The functional mushroom market in Europe is projected to reach USD 107 million by 2028. This partnership aims to leverage Avida's distribution network while aligning with Optimi’s goal to become a top supplier in the industry and exploring future sales of psilocybin mushrooms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. (CSE: OPTI, OTCQX: OPTHF) announced an operational update regarding its year of commercialization plan initiated in Q1 2022. The company focuses on producing EU-GMP grade psilocybin and synthetic psychedelics. Recent advancements in regulatory support are noted, with FDA approval for psychedelic therapy anticipated within 24 months. Optimi has secured multiple supply agreements and is positioned to launch its product catalogue, including Canada’s first therapeutic psilocybin product, Blue Serenity. The company is on track to begin large-scale MDMA production by October 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
none
-
Rhea-AI Summary

Optimi Health Corp. has entered its first international psilocybin supply agreement with Promises Innovative Recovery in Costa Rica. This partnership aims to establish a Center of Excellence for psychedelic-assisted mental health treatments, backed by Costa Rican regulatory advancements. CEO Bill Ciprick highlighted the importance of a consistent psilocybin supply for research and patient care. The company also appointed Justin Kirkland to their Medical & Clinical Advisory Board to enhance treatment protocols. This strategic move positions Optimi favorably in the growing psychedelic therapy market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
Rhea-AI Summary

Optimi Health Corp. announced three new distribution agreements for its Optimi Life nutraceutical mushroom products with Well.ca, Vitasave, and Healthy Planet. These deals enhance the company's B2B distribution network and are expected to facilitate its expansion into international markets. The agreements come shortly after the successful February launch of Optimi Life, which aims to meet the growing consumer demand for high-quality mushroom products. CEO Bill Ciprick highlighted the anticipated growth in the functional mushroom market, projected to expand by 9.5% annually over the next six years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.78%
Tags
management

FAQ

What is the current stock price of Optimi Health (OPTHF)?

The current stock price of Optimi Health (OPTHF) is $0.13915 as of February 20, 2025.

What is the market cap of Optimi Health (OPTHF)?

The market cap of Optimi Health (OPTHF) is approximately 14.3M.

What is Optimi Health Corp. specialized in?

Optimi is a Health Canada-licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances like botanical psilocybin and MDMA.

What recent milestone did Optimi achieve?

Optimi obtained a Drug Establishment Licence (DEL) from Health Canada, affirming its compliance with Good Manufacturing Practices (GMP) to supply MDMA and psilocybin capsules for patients.

What is Optimi's goal in the pharmaceutical industry?

Optimi aims to be the top trusted supplier of safe drug candidates globally by producing proprietary formulations in its 20,000 square feet facilities in Princeton, BC.

Where is Optimi's manufacturing facility located?

Optimi's manufacturing facilities totaling 20,000 square feet are located in Princeton, British Columbia.

What licenses does Optimi hold?

Optimi holds a Controlled Drugs and Substances Dealer's Licence and a Drug Establishment Licence (DEL), enabling the production of GMP-grade products and APIs.

How does Optimi plan to support global psychedelic research?

Optimi has completed its first international shipment of MDMA to Israel, supporting global research and innovation in the psychedelic field.

What is Optimi's key achievement in terms of export?

Optimi received the necessary Export Permit from Health Canada, confirming its ability to export controlled substances internationally.

What services does Oak Hill Financial Inc. provide to Optimi?

Oak Hill Financial Inc. provides comprehensive investor relations, business, and capital markets advisory services to Optimi at a rate of CDN$12,000 per month.

How does Optimi plan to expand its shareholder base?

Optimi aims to engage new investors and communicate its corporate milestones effectively through partnerships like Oak Hill Financial Inc.

What makes Optimi unique in the pharmaceutical industry?

Optimi's unique capabilities lie in producing scalable psychedelic formulations for transformational human experiences while meeting the highest quality and safety standards.
Optimi Health

OTC:OPTHF

OPTHF Rankings

OPTHF Stock Data

14.35M
58.12M
16.52%
0.05%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Garibaldi Highlands